Cutaneous reactions to adalimumab administration

Area of Science:

• Immunology
• Dermatology
• Rheumatology

Background:

• Antitumour necrosis factor-alpha (anti-TNFα) therapies are crucial for managing chronic inflammatory diseases like arthritis and inflammatory bowel disease.
• While effective, these biologic agents can elicit various adverse effects, including infections and autoimmune phenomena.
• Cutaneous reactions represent a known, yet incompletely characterized, spectrum of side effects associated with anti-TNFα treatment.

Observation:

• This report details two cases of patients with arthritis undergoing treatment with adalimumab, a specific anti-TNFα monoclonal antibody.
• Both patients presented with new-onset cutaneous eruptions during their course of adalimumab therapy.
• The observed rashes demonstrated a clear temporal relationship with the initiation of adalimumab treatment.

Findings:

• The development of new-onset rashes in patients treated with adalimumab was observed.
• Discontinuation of adalimumab therapy led to the resolution of these cutaneous reactions in both reported cases.
• These findings suggest a causal link between adalimumab and the observed skin adverse events.

Implications:

• The frequency and precise nature of adalimumab-induced cutaneous reactions require further investigation.
• Establishing a centralized registry for cutaneous reactions associated with anti-TNFα therapies could improve understanding and management.
• Clinicians should maintain a high index of suspicion for dermatological side effects in patients receiving adalimumab.